Cobra Biologics, now a Charles River company, is a leading international contract development and manufacturing organization (CDMO) specializing in premium plasmid DNA and viral vector services to support the Advanced Therapy Medicinal Products (ATMP) industry. Each of our GMP approved facilities are tailored to serving clients from early stage, to clinical, to commercial scale.
Our team takes pride in manufacturing excellence and supporting drug development for the benefit of patients worldwide. Our mission is to continue to expand and cultivate our CDMO offerings in the cell and gene therapy space, providing supply chain simplification through an end-to-end service for development, testing, and manufacturing.
Our team takes pride in manufacturing excellence and supporting drug development for the benefit of patients worldwide. Our mission is to continue to expand and cultivate our CDMO offerings in the cell and gene therapy space, providing supply chain simplification through an end-to-end service for development, testing, and manufacturing.
Services
As an experienced manufacturer of GMP viral vector products for ATMPs, gene therapies and vaccines, Cobra's goal since 2002 has been to deliver customers' viral vector programs in a cost effective and timely manner for clinical and commercial supply.
Cobra continues to develop robust and scalable process strategies for viral vector manufacturing and production for AAV, lentiviral vectors and adenoviruses, with media development and optimisation (animal component free), for both adherent and suspension modalities.
Cobra continues to develop robust and scalable process strategies for viral vector manufacturing and production for AAV, lentiviral vectors and adenoviruses, with media development and optimisation (animal component free), for both adherent and suspension modalities.
Non-GMP, High Quality (HQ), and GMP plasmid DNA manufacturing for preclinical and clinical supply. Since 1998, our success has come from the experience and expertise gained as a solution provider for gene and immunotherapies, known as Advanced Therapies (ATMPs), DNA vaccines and plasmid templates for mRNA therapies.
Cobra produced its first protein product in 1995 and since then has offered a broad range of integrated and stand-alone services now focusing on technical proteins. Cobra can provide cell banking and full GMP certification to support customers' protein projects. Working within cGMP manufacturing regulations, we can supply and maintain both Master & Working Cell Banks (MCB & WCB).
Our modern, flexible Fill Finish facility expands our service offering to include the production of sterile drug products and freeze drying / lyophilisation for clinical trials and commercial supply. Small molecules, DNA, recombinant proteins and antibodies can be filled into either prefilled syringes or vials.
Cobra provides a comprehensive biologics and pharmaceuticals service offering, with multi-functional and experienced project teams nurturing customers' products through to clinical and commercial manufacture within GMP approved facilities.
Cobra is a Contract Development and Manufacturing Organisation (CDMO) supporting the global life sciences industry in the development and manufacture of plasmid DNA, viral vectors, and technical proteins for clinical trials and commercial supply.
Cobra is a Contract Development and Manufacturing Organisation (CDMO) supporting the global life sciences industry in the development and manufacture of plasmid DNA, viral vectors, and technical proteins for clinical trials and commercial supply.
Reviews (1)
Nicole Bunny
Sep 22, 2018
Report
